EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis

Alexandru Zlibut, Michael Bietenbeck, Nuriye Akyol, Volker Vehof, Redouane Bouras, Khuraman Isgandarova, Claudia Meier, Maria Theofanidou, Philipp Stalling, Ali Yilmaz

Clinical Research in Cardiology · 2026

DOI: 10.1007/s00392-025-02691-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Alexandru Zlibut und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Magnetic Resonance Imaging, Cine, Benzoxazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives and background The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12 months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).

Methods

Patients with confirmed ATTR-CM ( N = 56) were divided into two groups: in the larger group A ( N = 39; 95% male), treatment with tafamidis 61 mg once daily was initiated after the first CMR study, whereas group B ( N = 17; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27 ± 6 months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.

Results

Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B ( p = 0.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48% p < 0.001 vs 56% to 46%, p < 0.001; −7.4 to −5.3, p < 0.001 vs −8.8 to −4.8, p < 0.001). However, the tafamidis-naïve group B experienced a substantially higher impairment of both parameters when compared to group A (∆p = 0.008 and ∆p = 0.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (from 18.2 mm to 21.1 mm at follow-up, p < 0.001) compared to the tafamidis-treated group A (from 18.5 mm to 19.2 mm, p = 0.012; ∆ p < 0.001). Both global native T1 and global ECV values were significantly elevated in both groups—at baseline and at follow-up—with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-naïve group B compared to the tafamidis-treated group A (group A: 51% to 57%, p < 0.001; group B: 50% to 67%, p < 0.001; ∆p < 0.001).

Conclusion

Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2 years. However, the “extent of worsening” is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesMagnetic Resonance Imaging, CineBenzoxazolesVentricular Function, LeftHumansMaleFemaleAgedMiddle AgedTime FactorsDisease ProgressionFollow-Up StudiesTreatment OutcomeRetrospective StudiesStroke VolumePeptide FragmentsNatriuretic Peptide, Brain

Stichwörter der Autor:innen

ATTRCMRCardiac amyloidosisTafamidis

Substanzen

tafamidisBenzoxazolespro-brain natriuretic peptide (1-76)Peptide FragmentsNatriuretic Peptide, Brain

Autor:innen und Institutionen

  • Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany.
  • Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany. Ali.Yilmaz@ukmuenster.de.

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Zlibut, A., Bietenbeck, M., Akyol, N., Vehof, V., Bouras, R., Isgandarova, K., Meier, C., Theofanidou, M., Stalling, P., & Yilmaz, A. (2026). CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02691-8

Vancouver

Zlibut A, Bietenbeck M, Akyol N, Vehof V, Bouras R, Isgandarova K, et al. CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02691-8

BibTeX
@article{Zlibut2026,
  author = {Zlibut, Alexandru and Bietenbeck, Michael and Akyol, Nuriye and Vehof, Volker and Bouras, Redouane and Isgandarova, Khuraman and Meier, Claudia and Theofanidou, Maria and Stalling, Philipp and Yilmaz, Ali},
  title = {CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-025-02691-8}
}
Kostenlos starten →